These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 28127851)

  • 1. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
    Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M;
    Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
    RISE Consortium
    Diabetes Care; 2014; 37(3):780-8. PubMed ID: 24194506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Habitual Daily Physical Activity With Glucose Tolerance and β-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study.
    Temple KA; Tjaden AH; Atkinson KM; Barengolts E; Hannon TS; Mather KJ; Utzschneider KM; Edelstein SL; Ehrmann DA; Mokhlesi B;
    Diabetes Care; 2019 Aug; 42(8):1521-1529. PubMed ID: 31177181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early mechanisms of glucose improvement following laparoscopic ileal interposition associated with a sleeve gastrectomy evaluated by the euglycemic hyperinsulinemic clamp in type 2 diabetic patients with BMI below 35.
    Vencio S; Stival A; Halpern A; Depaula CC; DePaula AL
    Dig Surg; 2011; 28(4):293-8. PubMed ID: 21894016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variants and haplotypes of TCF7L2 are associated with β-cell function in patients with newly diagnosed type 2 diabetes: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 1.
    Bonetti S; Trombetta M; Malerba G; Boselli L; Trabetti E; Muggeo M; Stoico V; Negri C; Pignatti PF; Bonora E; Bonadonna RC
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E389-93. PubMed ID: 21159844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
    RISE Consortium
    Diabetes Care; 2019 Sep; 42(9):1742-1751. PubMed ID: 31178434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test.
    RISE Consortium
    Diabetes Care; 2018 Aug; 41(8):1707-1716. PubMed ID: 29941498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes.
    Waldman B; Jenkins AJ; Davis TM; Taskinen MR; Scott R; O'Connell RL; Gebski VJ; Ng MK; Keech AC;
    Diabetes Care; 2014 Aug; 37(8):2351-8. PubMed ID: 24804699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
    Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK
    Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control.
    Choi SB; Lee JH; Lee JH; Kim S; Han SD; Kim IH; Noh YH
    Diabetes Metab Res Rev; 2013 Sep; 29(6):473-82. PubMed ID: 23592489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes.
    Matthews DR; Paldánius PM; Proot P; Foley JE; Stumvoll M; Del Prato S
    Diabet Med; 2019 Apr; 36(4):505-513. PubMed ID: 30576013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.